John Oyler Sells 3,680 Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 3,680 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $266.05, for a total value of $979,064.00. Following the sale, the chief executive officer now owns 1,460 shares of the company's stock, valued at approximately $388,433. This represents a 71.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

John Oyler also recently made the following trade(s):

• On Tuesday, June 17th, John Oyler sold 1,460 shares of BeOne Medicines stock. The shares were sold at an average price of $256.49, for a total value of $374,475.40.
• On Friday, June 6th, John Oyler sold 5,127 shares of BeOne Medicines stock. The stock was sold at an average price of $252.77, for a total value of $1,295,951.79.

BeOne Medicines Trading Down 0.5%

BeOne Medicines stock traded down $1.31 during trading hours on Wednesday, reaching $252.78. 230,441 shares of the company were exchanged, compared to its average volume of 447,828. BeOne Medicines Ltd. - Sponsored ADR has a 12 month low of $141.31 and a 12 month high of $287.88. The company has a current ratio of 1.96, a quick ratio of 1.71 and a debt-to-equity ratio of 0.05. The firm has a 50-day moving average price of $243.44. The firm has a market capitalization of $27.69 billion, a price-to-earnings ratio of -67.95 and a beta of 0.30.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $1.93. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. As a group, research analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ONC shares. TD Securities restated a "buy" rating and issued a $334.00 price objective on shares of BeOne Medicines in a report on Thursday, April 24th. Royal Bank Of Canada decreased their target price on shares of BeOne Medicines from $312.00 to $311.00 and set an "outperform" rating for the company in a research report on Thursday, May 8th. Sanford C. Bernstein set a $259.00 price target on shares of BeOne Medicines in a report on Thursday, March 13th. Bank of America raised shares of BeOne Medicines from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $207.00 to $320.00 in a research note on Monday, March 3rd. Finally, Macquarie upped their price objective on shares of BeOne Medicines from $259.00 to $313.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $319.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.